The NRF2 transcriptional target $NQO1$ has low mRNA levels in $TP53$-mutated endometrial carcinomas

Guillaume Beinse$^1$, Pierre-Alexandre Just$^{1,2,3}$, Bastien Rance$^{2,4}$, Brigitte Izac$^{1,5}$, Franck Letourneur$^{1,3}$, Nathaniel Edward Bennett Saidu$^{1,2}$, Sandrine Chouzenoux$^1$, Carole Nicco$^{1,2}$, François Goldwasser$^{2,6}$, Eric Pasman$^{1,2,7}$, Frederic Batteux$^{1,2,8}$, Bruno Borghese$^{2,9}$, Jérôme Alexandre$^{1,2,6}$*, Karen Leroy$^{1,2,7}$*.

1 INSERM U1016, Cochin Institute, CARPEM, Paris, France, 2 Paris Descartes University, Sorbonne Paris Cité, Paris, France, 3 Department of Pathology, Cochin Hospital, Assistance Publique–Hopitaux de Paris, Paris, France, 4 Department of Medical Informatics, HEGP, Assistance Publique–Hopitaux de Paris, Paris, France, 5 INSERM U1016, Cochin Institute, GENOMIC platform, Paris, France, 6 Department of Medical Oncology, Cochin Hospital, Assistance Publique–Hopitaux de Paris, Paris, France, 7 Department of Genetics and Molecular Biology, Cochin Hospital, Assistance Publique–Hopitaux de Paris, Paris, France, 8 Department of Immunology, Cochin Hospital, Assistance Publique–Hopitaux de Paris, Paris, France, 9 Department of Gynecologic Surgery, Cochin Hospital, Assistance Publique–Hopitaux de Paris, Paris, France.

☯ These authors contributed equally to this work.

* karen.leroy@aphp.fr

Abstract

Background

NRF2 is a major transcription factor regulating the expression of antioxidative/detoxifying enzymes, involved in oncogenic processes and drug resistance. We aimed to identify molecular alterations associated with NRF2 activation in endometrial carcinoma (EC).

Methods

Ninety patients treated (2012–2017) for localized/locally advanced EC were included in this study. Formalin-fixed paraffin-embedded tissue samples were processed for immunohistochemical (NRF2 and Mismatch Repair proteins) analyses. Next generation sequencing (NGS) of a panel of genes including $POLE$, $TP53$, $NFE2L2$, $KEAP1$ and $CUL3$ was performed using Ampliseq panels on Ion Torrent PGM (ThermoFisher). NRF2 activity was assessed by $NQO1$, $GCLC$, and $AKR1C3$ mRNA expressions, using TaqMan assays and quantitative RT-PCR.

Results

Tumors were classified as $POLE$ exonuclease domain mutated ($N = 3$, 3%), MMR-deficient (MSI-like) ($N = 28$, 31%), $TP53$ mutated (Copy-number high-like) ($N = 22$, 24%), and other tumors (Copy-number low-like) ($N = 32$, 36%). NRF2 nuclear immunostaining did not correlate with NRF2 target genes expression. The 3 tumors with highest NRF2 target genes expression harbored oncogenic $KEAP1$ or $NFE2L2$ mutations. Low $NQO1$ mRNA and
protein levels were observed in the \textit{TP53} mutated subgroup compared to others tumors ($p < .05$) and \textit{in silico} analyses of The Cancer Genome Atlas data further indicated that NQO1 mRNA levels were lower in serous compared to endometrioid copy-number high EC.

**Conclusion**

In contrast with previous reports based on immunohistochemistry, our study indicates that NRF2 activation is a rare event in EC, associated with \textit{NFE2L2} or \textit{KEAP1} mutations. The subset of aggressive EC with low NQO1 mRNA level might represent a specific subgroup, which could be sensitive to combination therapies targeting oxidative stress.

**Introduction**

Endometrial carcinoma is the most frequent gynecological cancer in woman. Two main histological types have been described, type 1 endometrioid carcinoma and type 2 including non-endometrioid subtypes (high grade serous, clear cell carcinoma, carcinosarcoma) with poorer prognosis [1]. This classification was refined in 2013 by an integrated genomic characterization [2], which allowed to identify four major molecular groups: 1/ an ultra-mutated group, with DNA-Polymerase $\varepsilon$ (\textit{POLE}) catalytic subunit A mutations; 2/ a hypermutated group, characterized by a somatic microsatellite instability (MSI), largely due to methylations in \textit{MLH1} promoter; 3/ a group characterized by low copy-number alterations (Copy-number low group (CNL)); and 4/ a group characterized by high copy number alterations (Copy-number high group (CNH)) and \textit{TP53} mutations, that includes most serous carcinoma and some high grade endometrioid histologic subtypes, and that carries the worst prognosis. Despite these new insights, therapeutic breakthroughs are still awaited.

Most tumor cells are characterized by their increased production of reactive oxygen species (ROS) within the mitochondrial respiratory chain in relation to high metabolic activity [3,4]. To regulate ROS homeostasis, tumor cells need to activate anti-oxidative stress (AOS) response elements, mainly through NRF2 activation, a transcription factor encoded by the gene \textit{NFE2L2}. At basal levels, NRF2 is bound to its repressor, Kelch-like ECH-associated protein 1 (KEAP1), which drives its ubiquitination by CUL3 and subsequent degradation in the proteasome. Increase in cellular ROS levels induces the disruption of the NRF2/KEAP1 couple thereby allowing NRF2 translocation into the nucleus and its binding to AOS response element (ARE) promoters [5–7]. NRF2 activates the transcription of thousands of genes belonging to multiple pathways [6,8] involved in cell detoxification and in a cell metabolism reprogramming in which glucose is redirected in the pentose phosphate pathway.

Deregulated NRF2 activation in solid tumors has been largely reported and could drive cancer progression, metastasis, and resistance to therapy [9]. The disruption of NRF2 binding to KEAP1 can be due to mutations in the binding domains of NRF2 or KEAP1 [10–12]. NRF2 activation may also be induced by the loss of its negative regulation by the PTEN/GSK3β axis [13], which regulates beta-TRCP CUL1 degradation pathway [3,14]. Moreover, \textit{NFE2L2} gene expression may be induced by the oncogenic activation of proliferative signaling pathways (such as \textit{KRAS}, \textit{BRAF}, \textit{MYC} mutations or overexpression) [15].

In clinical studies, NRF2 activation has been largely assessed by its nuclear translocation, using immunohistochemistry (IHC). In endometrial carcinoma, conflicting results were reported. Thus, NRF2 activation has been described as more frequent in serous carcinoma in one study [16], but was observed in a large subset of endometrioid carcinoma with PTEN loss.
in another one [13]. The main weakness of these studies was the restriction of the “NRF2 activation” definition to immunohistochemistry assays [17].

Our study aimed to identify molecular alterations associated with NRF2 transcriptional activation, and to explore its impact on prognosis, in a population of patients treated for localized or locally advanced endometrial carcinoma. Herein, we provide new insights allowing a better understanding about the role of NRF2 in endometrial carcinoma, and more particularly in aggressive TP53/CNH tumors, which contrasts with previous findings.

**Material and methods**

**Endometrial carcinomas tissue selection and DNA extraction**

The Cochin Hospital Endometrial Cancer cohort included all consecutive patients who underwent tumor biopsy or tumor resection in the Gynecological Department between 2012 and 2017 for uterine carcinoma, and for whom formalin-fixed paraffin embedded (FFPE) tissue samples were available for further analysis. Genomic DNA extraction was performed on the sample area with the highest cellularity, using the Maxwell 16 FFPE Plus LEV DNA Purification Kit (Promega, Charbonnières-les-Bains, France), according to the manufacturer’s instructions. Clinical and molecular analyses of the whole cohort are reported elsewhere (Beinse et al. under submission). For the present study, all patients with samples available for RNA extraction were considered. All patients gave written informed consent for somatic genetic analyses and data collection. This study was approved by the Paris ethic committee (CPPIDF1-2015—DAP22).

**Targeted sequencing using AmpliSeq and Ion Torrent technologies**

Targeted amplification and library preparations were performed with Ion AmpliSeq protocols. Libraries were clonally amplified on sequencing beads in emulsion PCR with Ion OneTouch. Sequencing was performed using Ion Torrent technology with Ion Torrent Personal Genome Machine (PGM) System (Life Technology, ThermoFisher Scientific, Courtaboeuf, France).

The first gene panel included the following genes: TP53, KRAS, PTEN, PIK3CA, PIK3R1, POLE, ERBB2, CTNNB1, RPL22, PPP2R1A, ARID1A, ARID5B, CTCF, FBXW7, FGFR2. This panel was designed using AmpliSeq Designer (version 4.47) on Human genome hg19. Overall, 440 amplicons were designed in 2 pools (S1 Method). For the present study, we report results for genes identifying endometrial carcinoma molecular subgroups (POLE exonuclease domain and TP53 mutations), and mutations in KRAS coding sequence or belonging to the PI3K pathway (PTEN, PIK3CA, PIK3R1). The second panel targeted the complete coding sequences of NFE2L2, KEAP1, and CUL3 (S2 Method). Mean depth sequencing was >100X for all amplicons of NFE2L2 and KEAP1, and for 37/42 amplicons of CUL3.

**Bio-informatics analysis of sequencing data**

Torrent Suite Software (v. 5.6) was used for sequencing data processing. TMAP (Torrent Mapping Alignment Program) software was used to perform reads processing and mapping on loaded genome (Hg19), using default parameters. Samples with mean read length <90 bp, mean depth <150X, uniformity of coverage <70%, were removed in subsequent analysis (see S1 Fig for flow-chart). Variant Caller Plugin was used for variant calling. Variant Caller’s parameters were chosen to allow variant detection with minimal stringency, in order to get a high sensitivity, and to preclude false-negative (Parameters provided in S3 Method). COSMIC database reference transcripts were used for variant call. Variants were filtered to include in the final manual reviewing all significant (p<0.0001, based on Phred quality score logarithmic
transformation), somatic non-synonymous variants (Global minor allele frequency <0.1% in 1000 Genomes Project database), with a coverage ≥ 50X. All selected variants were one by one reviewed manually (G.B. & K.L.) using the Integrative Genomics Viewer (IGV) tool [18,19] and automated annotations (dbSNP, 1000 Genome Project, UCSC common SNPs, COSMIC, Gene Ontology). Variants were assumed to be clonal or sub-clonal according to the analysis of the allele ratio distribution of all variants belonging to the same sample. Variants with lowest allele ratio reaching maximal Euclidean distance compared to all others were considered as sub-clonal.

Final annotations of KEAP1 and NFE2L2 mutations were performed manually on the basis of relevant literature, and using Cancer Genome Interpreter [20] (https://www.cancergenomeinterpreter.org) and OncoKB [21] (http://oncokb.org).

**Immunohistochemistry**

**Hormone receptors, TP53, and mismatch repair status.** The following immunohistochemistry assays were performed in routine practice: hormone receptors (estrogen (ER) and progesterone (PR)), TP53, and MSH6 and PMS2 to estimate the mismatch repair status. Immunohistochemistry was performed on a Leica Bond-III Autostainer using the Bond Polymer Refine Detection Kit (Leica Biosystem), according to the manufacturer’s instruction. The following primary antibodies were applied on 5μm FFPE tissue slides after appropriate heat-induced epitope retrieval (ER1 or ER2, Leica Biosystems): TP53 (DO-7; DAKO; 1:800 dilution), PMS2 (A16-4; Pharmingen; 1:300 dilution), MSH6 (44; LSBio; 1:50 dilution), ER (1D5; DAKO; 1:50 dilution), and PR (PgR636; DAKO; 1:300 dilution). Staining was categorized using a standard pathological system, with the staining intensity (+ to ++++) and the percentage of tumor stained cells (0 to 100%). Hormone receptors staining were considered positive if >+ and >10%, TP53 staining was considered abnormal if >+ and >10%, or in case of staining loss with positive endogenous control [22]. Mismatch repair deficiency was defined by the loss of staining of either PMS2 or MSH6 [23].

**NRF2 and NQO1 staining.** Immunohistochemistry was performed on a Leica Bond-III Autostainer, using the Bond Polymer Refine Detection System Kit (Leica Biosystem), according to the manufacturer’s instructions. Epitope retrieval was performed in ER2 buffer (EDTA based buffer and surfactant, pH = 9) for 30 min at 95˚C for NRF2 staining and in ER1 buffer (EDTA based buffer and surfactant, pH = 6) for 20 min for NQO1 staining. Primary NRF2 antibody (Santa-Cruz Biotechnology A-10, sc-365949) was applied at 1:100 dilution for 1 h at room temperature. Primary NQO1 antibody (SIGMA-ALDRICH, HPA007308) was applied at 1:150 dilution for 20 min at room temperature. Slides were counterstained in hematoxylin and mounted in Pertex mounting medium (CellPath). Staining was categorized using a standard pathological system, with the staining intensity (+ to ++++) and the percentage of tumor stained cells (0 to 100%). Samples were considered NRF2-high if nuclear staining intensity was +++ in more than 50% of tumor cells, and intermediate (++/<50% and ++/<50%), low (++/<50% and +/<50%), or negative (+/<50% and 0).

**RNA extraction**

RNA extraction was performed using the Maxwell 16 LEV RNA FFPE Kit according to the manufacturer’s instructions. Briefly, 10 μm sections from FFPE samples (maximum 1 mm³) were immersed in mineral oil and heated (5 minutes at 80˚C) for deparaffinization. Samples were then lysed with proteinase K solution (15 minutes at 56˚C, and 60 minutes at 80˚C), treated with DNase I, and finally automatically processed on magnetic beads.
Gene expression assay

Reverse transcription (RT) was performed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystem, ThermoFisher Scientific), with up to 1400 ng of RNA (or up to 14μL of RNA sample for samples with the least yields) in a 20μL RT reaction. Samples were incubated in 1X RT buffer, 4mM dNTP mix, with 1X random primers, and 2.5U Multiscribe Reverse Transcriptase, during 10 minutes at 25˚C, 120 minutes at 37˚C, and 5 minutes at 85˚C. Complementary DNA (cDNA) obtained were diluted to 1:5 in RNase-free water (final volume: 100μL) before quantitative PCR (qPCR).

qPCR were performed using TaqMan Gene expression assays (ThermoFisher Scientific) in a 20μL reaction with LightCycler 480 Probes Master (Roche Diagnostics, Basel, Switzerland) on LightCycler 480 System Instrument (Roche Diagnostics), using 3 μL of cDNA, 1 μL of 20X TaqMan primer-probe mix, 10 μL of 2X LightCycler 480 Probes Master mix, and RNase-free water up to 20 μL. After incubation at 95˚C for 10 minutes, the reactions underwent 45 cycles as follow: 10 sec at 95˚C, 30 sec at 60˚C, and 1 sec at 72˚C,. Duplicate qPCR were performed on three core NRF2 target genes: *NQO1* (TaqMan probes ID Hs01045993_g1), *AKR1C3* (TaqMan probes ID Hs00366267_m1), and *GCLC* (TaqMan probes ID Hs00155249_m1), and two housekeeping genes: *TBP* (TaqMan probe ID Hs00427621_m1) and *MRPL19* (TaqMan probes ID Hs00608519_m1). Nine samples showing more than 3 genes with Cq ≥35 were excluded (S1 Fig). Quantifications results are presented as: \( \text{DeltaCq} = -[\text{Cq}_{\text{Gene}} - \text{mean(Cq}_{\text{TBP}}, \text{Cq}_{\text{MRPL19}}) \] so that positive values represent high expression and negative values represent low expression.

Statistical analysis

Correlations between qualitative and continuous variables were analyzed using Student t-test, or, if inapplicable, non-parametric test (Wilcoxon test). Correlations between continuous variables were analyzed using logistic regression. Correlations between qualitative variables were assessed using Fisher’s exact test. Clustering analysis based on NRF2 target genes expressions used principal component analysis. Survival analyses were assessed by logistic regression using the Cox regression model. Primary event of interest was event free survival (EFS), defined as any event (progression, relapse, or death), censored by date of last news. Evaluation of the proportional hazard assumption was based on the Schoenfeld residuals method. Kaplan-Meier survival analysis used two-sided log-rank test. Statistical significance was defined by \( p < 0.05 \). All analyses were performed using R software v3.3.3.

Results

Classification of endometrial carcinoma according to TCGA molecular subgroups

Among 159 consecutive endometrial carcinoma patients treated at Cochin Hospital between 2012 and 2017, 125 patients had tumor DNA available for molecular analyses and 90 could also be analyzed at the RNA level (S1 Fig). Tumor classification was based on *POLE* exunuclease domain mutation, mismatch repair protein loss of expression and *TP53* mutation, to retrieve TCGA molecular subgroups [2], as described in previous studies[24,25]. Population characteristics and tumor’s features are provided in Table 1. Overall, 3 out of 90 tumors (3.3%) harbored a mutation into the POLE exunuclease domain, defining POLE mutated tumors (*ultramutated-like*); 28 tumors (31.1%) had lost expression of PMS2 or MSH6, defining MMR deficient tumors (*MSI-like*); 22 (24.4%) tumors were mutated within the TP53 coding sequence, defining a TP53 molecular group (*CNH-like*). Finally, 32 tumors (35.6%) had no
Table 1. Clinical and pathological characteristics in the overall population and according to NRF2 nuclear staining.

| Characteristic                        | Overall population N = 90 | NRF2 nuclear staining \( ^a \) (N = 89) | \( p^b \) |
|---------------------------------------|---------------------------|------------------------------------------|----------|
| Age at surgery or diagnostic, median [min – max] (years) | 66.2 [44.0–94.3] | - | - | 0.80 |
| Histological main type, N (%)         |                           |                                          |          |
| Type I carcinoma                       | 73 (81.1%)                | 17 (23.6%)                               | 55 (76.4%) |
| Grade I endometrioid carcinoma         | 42 (46.6%)                |                                          |          |
| Grade II endometrioid carcinoma        | 24 (26.7%)                |                                          |          |
| Grade III endometrioid carcinoma       | 7 (7.8%)                  |                                          |          |
| Type II carcinoma                      | 17 (18.9%)                | 5 (29.4%)                                | 12 (70.6%) |
| Serous carcinoma                       | 10 (11.1%)                |                                          |          |
| Carcinosarcoma                         | 5 (5.6%)                  |                                          |          |
| Clear cell carcinoma                   | 2 (2.2%)                  |                                          |          |
| Tumor FIGO stage\( ^c \), N (%)       |                           |                                          | 0.85     |
| Localized                              | 61 (67.8%)                | 16 (26.7%)                               | 44 (73.3%) |
| IA                                     | 31 (34.4%)                |                                          |          |
| IB                                     | 29 (32.2%)                |                                          |          |
| II                                     | 1 (1.0%)                  |                                          |          |
| Locally advanced / metastatic          | 27 (30.0%)                | 6 (22.2%)                                | 21 (77.8%) |
| IIIA                                   | 2 (2.2%)                  |                                          |          |
| IIIB                                   | 1 (1.0%)                  |                                          |          |
| IIIC1                                  | 5 (6.0%)                  |                                          |          |
| IIIC2                                  | 12 (13.3%)                |                                          |          |
| IVB                                    | 7 (7.7%)                  |                                          |          |
| Missing data                           | 2                         |                                          |          |
| Lymphatic or vascular invasion, N (%)  |                           |                                          | 0.23     |
| No                                     | 61 (67.8%)                | 18 (30.0%)                               | 42 (70.0%) |
| Yes                                    | 24 (28.2%)                | 3 (12.5%)                                | 21 (87.5%) |
| Missing data d                         | 5                         |                                          |          |
| Hormone receptors, N (%)               |                           |                                          |          |
| Estrogen receptor                      |                           |                                          | 0.79     |
| \(<10\%+/\)                           | 15 (16.7%)                | 3 (20.0%)                                | 12 (80.0%) |
| \(\geq10\%+/\)                        | 75 (83.3%)                | 19 (25.7%)                               | 55 (74.3%) |
| Missing data                           | 0                         |                                          |          |
| Progesteron receptor                   |                           |                                          | 1.00     |
| \(<10\%+/\)                           | 33 (37.9%)                | 7 (21.2%)                                | 26 (78.8%) |
| \(\geq10\%+/\)                        | 54 (62.1%)                | 12 (22.6%)                               | 41 (77.4%) |
| Missing data d                         | 3                         |                                          |          |
| TP53 immunostaining, N (%)             |                           |                                          | 0.39 *   |
| Normal (Wild-type-like)                | 61 (67.8%)                | 15 (24.6%)                               | 46 (75.4%) |
| Overexpression                         | 24 (26.7%)                | 6 (26.1%)                                | 17 (73.9%) |
| Loss of expression                     | 2 (2.2%)                  | 0 (0.0%)                                 | 2 (100.0%) |
| Missing data d                         | 3                         | 1                                        | 2 \( ^f \) |
| Molecular group \( ^f \), N (%)       |                           |                                          | 0.13 * \( ^g \) |
| POLE (ultramutated-like)               | 3 (3.3%)                  | 0 (0.0%)                                 | 3 (100.0%) |
| MMR deficient (MSI-like)               | 28 (31.1%)                | 4 (14.3%)                                | 24 (85.7%) |
| TP53 (CNH-like)                        | 22 (24.4%)                | 8 (36.4%)                                | 13 (59.0%) |
| MMR proficient (CNL-like)              | 32 (35.6%)                | 9 (28.1%)                                | 23 (71.9%) |

\( ^a \) Indicates NRF2 nuclear staining categories.

\( ^b \) Indicates statistical significance levels.

\( ^c \) Indicates FIGO tumor stage categories.

\( ^d \) Indicates missing data categories.

\( ^e \) Indicates TP53 immunostaining categories.

\( ^f \) Indicates molecular group categories.

\( ^g \) Indicates statistical significance levels.

\( ^h \) Indicates molecular group categories.

\( ^i \) Indicates TP53 immunostaining categories.

(Continued)
aforementioned alteration, defining a copy-number low-like group (CNL-like). The distributions of histological types and molecular groups were consistent with endometrial carcinoma epidemiology, and previously published data [1,2].

**NRF2 expression and transcriptional activity in endometrial carcinoma**

We assessed NRF2 nuclear staining using immunohistochemistry on FFPE sections (Fig 1). Nuclear staining was not observed into the nuclei of normal epithelial and stromal cells. For some surgical specimens, we observed a variability of NRF2 staining in tumor cells within the same section, possibly due to formalin-fixation artifacts for large surgical specimens. Therefore, for these specimens, NRF2 staining was considered only for morphologically well-fixed regions (i.e. without morphological degradation). When scoring the staining by intensity (+ to ++++) and extension (0 to 100% of tumor cells), we were able to identify a subset of tumors with high NRF2 nuclear staining (+++ in more than 50% of tumor cells) (N = 22, 24.7%) (Table 1). No tumor pathological nor clinical features was significantly associated with this high NRF2 nuclear staining (Table 1) although we observed a trend towards a higher proportion of NRF2-high tumors in the TP53/CNH-like tumors (36.4% versus 19.4% in non-TP53/CNH-like tumors, p = 0.052).

As NRF2 is a transcription factor with well-known target genes [3,4], we analyzed the mRNA levels of three of its target genes (NQO1, GCLC, AKR1C3). NQO1 was chosen because involved in phase II xenobiotic detoxification and in NADPH consumption. GCLC was chosen because being involved in glutathione production, considered as the most abundant anti-oxidant cellular cofactor. Finally, aldo-keto-reductase genes have been reported to be among the most inducible NRF2 targets in human systems [26]. Overall, NQO1, AKR1C3 and GCLC mRNA levels of expression were correlated with each other (Pearson correlation coefficient for NQO1/AKR1C3 = 0.41, NQO1/GCLC = 0.41 and GCLC/AKR1C3 = 0.55) and highly variable within the whole cohort (S2 Fig). No statistical association was observed between NRF2 high nuclear staining and NRF2 target genes expression (Fig 2), indicating that nuclear staining is not representative of NRF2 activity and appears as a poor surrogate marker of NRF2 transcriptional activation in these tumors.

### Table 1. (Continued)

| Missing data d | Overall population N = 90 | NRF2 nuclear staining \(^*\) (N = 89) | \(p^b\) |
|----------------|--------------------------|-------------------------------|------|
|                | N = 90 (100%)            | High                         | Others |
| Missing data d | 5 (4.4%)                 | 1                            | 4     |
| Total          | 90 (100%)                | 22 (24.7%)                   | 67 (75.3%) |

* data missing for one patient (see #); NRF2-high: staining intensity of +++ in more than 50% of tumor cells.

b p-values estimated with Fisher exact test.

c International Federation of Gynecology and Obstetrics (FIGO) 2010 staging.

d data missing because of technically uninformative immunostaining test. <\>/=10%+/+: hormone receptor staining intensity \(\geq\) in \(\geq\) 10% of tumor cells.

f based on POLE and TP53 targeted sequencing and mismatch repair (MMR) proteins immunostaining–MSI: microsatellite instability. CNH: copy-number high. CNL: copy-number low. Tumors with a mutation in the POLE exonuclease domain are classified as POLE tumors, tumors with a defect of expression of one MMR protein were classified as MMR deficient (microsatellite instable-like) tumors, tumors with TP53 mutations are classified as TP53 molecular group (copy number high-like), and all others are classified as MMR proficient (copy number low-like) tumors.

g Fisher test was performed using molecular subgroup as one categorical variable, without consideration of POLE because there was no subject in one group.

https://doi.org/10.1371/journal.pone.0214416.t001
NFE2L2/KEAP1 mutations in endometrial carcinoma and NRF2 target gene expression

Molecular alterations within the NRF2 pathway were assessed using next-generation sequencing with a dedicated panel that included NFE2L2, KEAP1, and CUL3 coding sequences. With a mean coverage of 880X per sample, 1924 variants were identified. After filtering for germline polymorphisms, non-coding and silent variants, and low-quality calls, 127 variants were selected for manual reviewing. After exclusion of sequencing artifacts, 16 variants (Table 2) were considered for manual annotation based on literature [10,12,27] and database annotation (Cancer Genome Interpreter [20] and OncoKb [21]). Eight variants were identified in NFE2L2, among which 3 (NRF2 p.W24G, p.E82D and p.G81V) were located at known hotspot positions known to disrupt KEAP1 binding. Among the five other variants, four were annotated as passenger mutations. The last one (NRF2 p.R499W) was predicted in silico as driver, nevertheless the absence of supporting experimental evidence and its association with

Fig 1. Representative NRF2 immunostaining in endometrial tumors. Immunohistochemical assay using NRF2 (clone A-10, SantaCruz) monoclonal antibody, revealed with Leica Bond Polymer Refine Detection System kit. 10X objective. A: endometrioid grade I, copy number low-like tumor–stage IB. NRF2 high case. B: serous carcinoma copy-number low-like tumor, stage IIIC2–NRF2 high case. C: carcinosarcoma, copy number high-like tumor–stage IB. NRF2 intermediate case. D: endometrioid grade I, copy number low-like tumor–stage IB. NRF2 negative/low case. Note that: A: sample with NRF2 activating mutations (KEAP1 p.R336G).
deleterious KEAP1 variants precluded a definitive assessment regarding its pathological function. Five variants were found in KEAP1, among which 2 were expected to affect NRF2 binding: p.D422N, which is a recognized oncogenic mutation and p.R336\*, which is a non-sense truncating mutation. For the 3 other variants, there was no available functional data that support a deleterious function, although 2 of them (p.G350R and p.G509R) were located in the protein domains involved in NRF2 binding. Of note, 2 samples harbored several variants and some variants were suspected to be sub-clonal considering the distribution of variant allele frequency within the tumors (Table 2). Overall, 5 samples harbored known NRF2 pathway activating mutations. The 3 samples with CUL3 mutations did not harbor high NRF2 target expression, or had concomitant NRF2-activating mutations.

The three samples with high mRNA levels for all three NRF2 target genes harbored mutations affecting the NRF2/KEAP1 binding (Fig 3, and Table 2). NRF2 nuclear staining of these three tumors was considered as high (N = 2) or intermediate (N = 1). Two other samples with likely oncogenic NFE2L2 variants at low allele ratios had an intermediate/high expression of these three target genes (first quartile). Because of the limited number of samples, no formal relevant statistical test could be performed. However, using a principal component analysis based on these three NRF2 target genes expression to cluster samples, we found an overlap between samples belonging to the four molecular subgroups, contrasting with a distinct cluster including the three samples harboring clonal NRF2 activating mutations (NRF2 group) (S3 Fig). The same type of analysis was applied to the TCGA cohort data, highlighting the existence of a small group of tumors with pathogenic NFE2L2/KEAP1 mutations and high NRF2 target genes expression (S4 and S5 Figs). These data indicate that strong NRF2 transcriptional activation in endometrial carcinoma is related to specific NFE2L2/KEAP1 mutations and independent of the molecular endometrial carcinoma subgroups.

Molecular and histo-pathological features associated with NQO1 mRNA level

A subset of outlier tumors showed a low NQO1 mRNA level, depicted in dark grey bars in Fig 3 on the basis of a gap in the NQO1 expression distribution. These tumors had variable mRNA levels of GCLC and AKR1C3 and various NRF2 staining intensity (high: N = 2; intermediate: N = 4; low: N = 3). This prompted us to search for histological, pathological or molecular features associated with a low NQO1 mRNA level. We observed a lower NQO1 mRNA level in
Table 2. NRF2 pathway mutations and NRF2 target gene expression.

| Patient | Histological type | Molecular subgroup | NQO1 deltaCq | GCLC deltaCq | AKR1C3 deltaCq | GENE, variant | Allele ratio | CGI | Onco Kb | Affects domains known to be involved in NRF2/KEAP1 binding | Known association with NRF2 pathway activation | Comments and references |
|---------|-------------------|-------------------|--------------|-------------|----------------|---------------|--------------|-----|--------|-----------------------------|-------------------------------------------------|-------------------------|
| A       | Mucinous MSI      | 5.53              | 2.47         | 3.52        | NFE2L2, p.W24G | 34%           | Tier 1       | aa 24 : LO | Yes (DLG motif) | Yes | Located at NFE2L2 Exon 2 hotspot (although different aminoacid change) |
| B       | Endometrioid (grade I) | CNL   | 4.81         | 2.74         | 4.63           | NFE2L2, p.R499W/KEAP1, p.R336 | 37%           | Tier 1       | -    | No | KEAP1 truncating mutation |
| C       | Serous TP53       | 4.48              | 1.91         | 3.64        | KEAP1, p.D422N | 75%           | Tier 1       | O   | Yes | Yes | KEAP1 mutation in the NRF2/KEAP1 binding domain |
| D       | Endometrioid (grade I) | MSI   | 3.41         | 0.88         | 1.27           | KEAP1, p.R169H/CUL3, p.Q188H/KEAP1, p.G350R/NFE2L2, p.E82D | 51%           | Tier 1       | -    | No | |
| E       | Endometrioid (grade II) | MSI   | 3.39         | 0.41         | 0.77           | NFE2L2, p.S137L | 13%           | Passenger   | -    | No | |
| F       | Endometrioid (grade I) | MSI   | 2.42         | 0.36         | 0.65           | NFE2L2, p.G81V | 16%           | Tier 1       | LO   | Yes (ETGE motif) | Yes | NFE2L2 Exon 3 hotspot–suspected subclonal |
| G       | Endometrioid (grade II) | POLE  | 2.27         | 0.94         | 0.31           | NFE2L2, p.K599Q | 12%           | Passenger   | -    | No | |
| H       | Endometrioid (grade II) | MSI   | 1.90         | -1.40        | -7.23          | CUL3, p.D121E | 42%           | Tier 1       | -    | No | |
| I       | Endometrioid (grade III) | POLE  | 1.71         | 0.23         | -1.41          | NFE2L2, p.S137L | 8%            | Passenger   | -    | No | |
| J       | Endometrioid (grade II) | MSI   | 0.92         | -0.29        | -1.87          | CUL3, p.R588Q | 28%           | Tier 1       | -    | No | |
| K       | Endometrioid (grade III) | CNL   | -0.74        | -0.50        | -2.78          | NFE2L2, p.Q171R | 25%           | Passenger   | -    | No | |

CGI: Cancer Genome Interpreter (https://www.cancergenomeinterpreter.org/home); Tier 1: predicted driver with high level of stringency based on OncodriveMUT interpretation on CGI. OncoKB: http://oncokb.org; LO: likely oncogenic, according to OncoKB annotation; O: oncogenic, according to OncoKB annotation. aa: aminoacid. Boxes colored in grey highlight values in upper quartile in the expression distribution of the considered gene. POLE: ultramutated-like tumors, with mutation within the POLE exonuclease domain; MSI: MSI-like tumors, with mismatch repair system protein loss of expression; CNL: copy-number low-like tumors; TP53: copy-number high-like tumors, without POLE mutation or mismatch repair system deficiency, while affected by TP53 mutation. Refseq sequences used for variant call: NFE2L2: NM_006164.4; KEAP1: NM_203500.1; CUL3: NM_003590.4. 

https://doi.org/10.1371/journal.pone.0214416.t002
type II carcinoma (Fig 4A) and in tumors bearing a TP53 alteration in immunohistochemistry assay (Fig 4B). As shown on Fig 4C, we also observed a low NQO1 mRNA level in the TP53/CNH-like molecular subgroup. This observation was consistent with RNA-sequencing data analysis from TCGA endometrial carcinoma dataset (Fig 4D) (data set from the www.cbioportal.org platform [28,29]; Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013) [2]). GCLC and AKR1C3 mRNA levels were not decreased in the CNH molecular group (S6 Fig). Finally, because of the histopathological heterogeneity of the TP53/CNH-like molecular group, which includes type II carcinomas (N = 13, 56.5%), and also type I endometrial carcinomas (N = 9, 40.1%), we wondered whether a low NQO1 mRNA level could be related to the histological type or estrogen receptor positivity. We did not observe any significant difference in our cohort (S7 Fig), but the statistical power was weak (N = 22). However, when exploring the TCGA CNH group, we observed a significantly lower NQO1 mRNA level in serous carcinoma, compared to endometrioid carcinoma (Fig 4E). In order to confirm that a low NQO1 expression was indeed observed in TP53/CNH-like tumors despite the trend for higher NRF2 staining, we assessed NQO1 protein expression in 22 samples (Fig 5). The 5 samples with NQO1 mRNA level in the highest quartile were scored NQO1-high and 4 out of these harbored known NRF2 activating mutations. The 6 samples with NQO1 mRNA level in the lowest quartile were scored NQO1 weak/negative and belonged to the TP53/CNH-like molecular group. Intermediate levels of NQO1 mRNA expression (Q2, Q3) showed high (n = 1), intermediate (n = 6) or weak/negative (n = 4) NQO1 staining. These findings indicate a low mRNA level of NQO1 in the TP53/CNH-like group and suggest that the mechanisms regulating NQO1 mRNA level may vary within the CNH group depending on histological type.

Several studies reported the relations between NRF2 activation and PI3K pathway activation in endometrial carcinoma [13], or KRAS mutations in other tumor types [15,30]. In our
Low NQO1 mRNA level in TP53 mutated endometrial carcinoma

A. NQO1 expression and histological type (CCH)

B. NQO1 expression and TP53 staining (CCH)

C. NQO1 expression and molecular group (CCH)

Kruskal-Wallis, p = 0.0071

D. NQO1 expression and molecular group (TCGA)

E. NQO1 expression and histological type within copy-number high molecular group - TCGA cohort

F. Event free survival and NQO1 expression

p = 0.00049

Number at risk

NQO1 normal or high

NQO1 low

0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90

Endometrioid  Serous

Histological type

POLE MSI TP53 CNL

Molecular group

POLE MSI Copy-number high Copy-number low

NS NS NS NS

Anova, p = 6.6e-05

0 5 10 15 20

NQO1 expression (log2(RSEM V2 RNASeq))

0 0.25 0.5 0.75 1.0

Event-free-survival (%)

Months
cohort, no significant association was observed between PIK3CA, PIK3R1, or PTEN mutations, and NQO1, GCLC, or AKR1C3 expression (S8 Fig). The only significant association found was a higher NQO1 expression in KRAS mutated tumors (p = 0.033, S9A Fig). This association was probably due to a bias related to the high frequency of KRAS mutation in non-TP53 mutated tumors and was not confirmed when performing this analysis after removing TP53/CNH-like

Fig 4. NQO1 expression in endometrial carcinoma. NQO1 expression was measured by quantitative RT-PCR in Cochin Hospital cohort (CCH) and RNAseq in The Cancer Genome Atlas Cohort (TCGA). TCGA data was obtained from the www.cbioportal.org platform [28,29]; Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013) [2]. NS: non-significant (p > 0.05); *, **, ****: p-values, respectively: <0.05; <0.01; <0.001; <0.0001. Dots depicted as crosses refer to tumors considered as NRF2 activated in the Cochin cohort, as shown on Fig 3 A. NQO1 expression and histological type (CCH). Type I and type II refer to histological subtypes (Table 1). B. NQO1 expression and TP53 staining. Altered TP53 staining considered both staining with overexpression or staining with loss of expression. C. NQO1 expression and molecular group (CCH). POLE: POLE exonuclease domain mutated tumors. MSI: microsatellite instable-like tumors. TP53: TP53/copy-number high-like tumors. CNL: copy number low-like tumors. Paired comparisons computed using post-hoc test adjusted for the risk of multiple comparisons. POLE tumors were not included in statistical test because of the number of samples in the group (<5). D. NQO1 expression and molecular group (TCGA). POLE: POLE tumors. MSI: microsatellite instable tumors. Anova: analysis of variance. p-values are depicted in * to **** for graphical purposes. Paired comparisons computed using post-hoc test adjusted for the risk of multiple comparisons. E. NQO1 expression and histological type within copy-number high group. TCGA data. p-value based on Student t-test. F. Event free survival and NQO1 expression. Kaplan-Meier curves. p-value based on two-sided log-rank test.
tumors ($p = 0.26$, S9B Fig). The analysis of the TCGA data further confirmed the absence of correlation between high NRF2 target expression and mutation of KRAS, PIK3CA, PIK3R1 and PTEN (S5 Fig).

**Association between NQO1 mRNA level and prognosis**

Ninety patients were included in the survival analysis (EFS). Median follow-up was 24.1 months (interquartile range: [13.8;43.7]–reverse Kaplan-Meier method[31]). As shown in Fig 3A, nine samples had a low NQO1 mRNA level. Patients belonging to this subgroup exhibited a poor prognosis (1-years EFS = 47.6%, 95% confidence interval (95%CI) [22.0; 100.0]–Fig 4F) when compared to patients without low NQO1 mRNA level (1-years EFS = 84.0%, 95%CI [75.8; 93.2] (Univariate hazard ratio (HR) = 4.66, 95%CI[1.80; 12.1], $p = 0.002$)). However, in an adjusted Cox regression model that includes the TP53/CNH-like molecular group as main confounder, low NQO1 mRNA level was not independently associated with poorer survival (adjusted-HR = 1.7, 95%CI[0.6; 5.3], $p = 0.3$), while TP53/CNH-like molecular subgroup was (HR = 4.02, 95%CI[1.44; 11.3], $p = 0.008$). These results show an association between low NQO1 mRNA level and poor outcomes but were underpowered to explore subgroup analysis according to NQO1 mRNA level within the TP53/CNH-like molecular group.

**Discussion**

We report here a comprehensive analysis of the NRF2 activation process in endometrial carcinoma using genes expression data, genetic characterization, protein expression/subcellular location assay. In contrast with previous reports [16,32], despite 24.7% of samples showing a high NRF2 nuclear staining, we observed a cluster of only 3 out of 90 (3%) cases with NRF2 activating mutations and a concomitant overexpression of three core target genes. This finding suggests that NRF2 activation driven by molecular alterations affecting NRF2/KEAP1 binding is a rare event in endometrial carcinoma. On the other hand, we observed a strikingly low NQO1 expression in aggressive TP53/CNH-like tumors. This finding was also in contrast with conventional models suggesting that the high ROS production in aggressive tumor cells activates NRF2 in order to increase detoxification genes expression, such as NQO1, and to sustain a high proliferative rate [4].

We have observed a strong trend toward more NRF2 highly stained tumors within the TP53/CNH-like group, known to be of poor prognosis [2], consistent with previous reports describing higher NRF2 expression with advanced stage and high tumor grade in endometrial carcinomas [32]. However, we did not observe any association between high NRF2 staining and its target genes expression. This could be due to several issues. First, the NRF2 antibodies specificity has been described to be potentially limited [17]. No gold-standard is for now available for NRF2 immunohistochemistry assay. In some reports, NRF2 staining has been observed in the cytoplasm. We considered the staining into the nuclei as consistent with NRF2 physiology, NRF2 being described as constantly degraded in the cytoplasm [3]. The observation of cytoplasmic staining could be related to non-specific staining related to antibody specificity issues [17] or different antigen retrieval methods. On the other hand, the sequencing results were consistent with TCGA in-silico data analysis, based on exome sequencing, while the qPCR expression results led to similar conclusions when faced to TCGA RNA-sequencing data. Our results indicate that assessing NRF2 core target genes expression appears more reliable than immunohistochemistry to assess NRF2 activation.

Recent studies have reported the involvement of NRF2 in biological processes others than its canonical role in cell detoxification and metabolism reprogramming. As reported by Kalo et al. [33] and more recently by Walerych et al. [34], in tumor cells affected by TP53
missense mutations, NRF2 cooperates with TP53 mutant isoforms and colocalizes on proteasome gene promoters, subsequently inhibiting multiple tumor suppressive pathways and driving an aggressive phenotype. Importantly, this phenomenon precludes NRF2 binding on ARE promoters, and induces a downregulation of various AOS genes, more particularly phase II detoxification genes, such as NQO1 or HMOX1, or SLC7A11 [34,35]. Subsequently, these tumors were shown to reach higher ROS levels. The observation that endometrial TP53/CNH-like tumors, especially tumors with serous histology, have very low NQO1 mRNA levels could be related to NRF2/TP53 cooperation and may have interesting clinical implications. The observation that serous carcinoma are initially highly sensitive to chemotherapy [36] could be related to this NRF2 downregulation, which would limit the detoxification capacities of the tumor cells. NRF2/TP53 cooperation were shown to be targeted in vivo by specific combination therapies [34,35]. For instance, the addition of a missense mutant TP53 inhibitor APR-246 to the proteasome inhibitor Carfilzomib has been demonstrated to be active in vivo on triple-negative breast cancer models, a tumor carrying a molecular background similar to CNH endometrial carcinoma [34]. Another example is the sensitivity of these tumors to inhibitors of the cystine/glutamate antiporter [35], which deplete GSH in TP53 mutated cells, resulting in an oxidative burst and cell death. Indeed, the identification of such biological oncogenic process in endometrial tumors could help to select patients with particularly poor outcomes who could take advantage of these new therapeutic approaches. On the other hand, NQO1 regulation may involve other transcriptional factors and its low expression in a subset of endometrial carcinomas might be related to biological processes independent of NRF2: an extensive chromatin and transcriptomic analysis of these tumors would be required to determine whether NRF2 transcriptional program is indeed skewed in TP53 mutated serous tumors. Finally, because the interplay described between NF-kB and NRF2 [37], tumors with low NQO1 expression belonging to the TP53/CNH-like group could be affected by higher NF-kB activity, which could imply more inflammation. Further studies are warranted to confirm whether this feature could participate to aggressiveness of this molecular subgroup.

In conclusion, our work suggests that NFE2L2/KEAP1 mutations leading to a strong NRF2 activation is a rare event in endometrial carcinoma, and that a subset of TP53/CNH-like endometrial carcinoma with serous histology have low NQO1 expression, that could be related to a NRF2/TP53 cooperation. This last phenomenon could drive their aggressiveness, although making them initially more sensitive to chemotherapy. If confirmed, new therapeutic approaches and combinations should be investigated in this subgroup of CNH endometrial carcinoma.

Supporting information

S1 Fig. Study flow chart. NGS: next generation sequencing, performed on IonTorrent PGM device. FFPE: formalin-fixed paraffin embedded. cDNA: coding DNA after reverse transcription. * one patient with 2 samples processed for sequencing, without qualitative changes on results. Sample with highest cellularity and best conservation was processed for RNA extraction.

S2 Fig. Distribution of NRF2 target genes expressions. NQO1, GCLC and AKR1C3 expressions measured by quantitative RT-PCR are shown as 3D scatter plot. Axis: Color palette from dark blue to dark red follow NQO1 deltaCq expression. Plan is the NQO1 bidimensionnal regression plan according to GCLC and AKR1C3 expression (Pearson correlation coefficient
for NQO1/AKR1C3 = 0.41, NQO1/GCLC = 0.41 and GCLC/AKR1C3 = 0.55).

S3 Fig. Endometrial carcinoma clustering based on NRF2 target genes expressions, based on principal component analysis. Clustering was based on principal component analysis. PC1 and PC2: principal component 1 and 2. CNL: copy-number low-like tumors. MSI: microsatellite instable-like tumors. NRF2: tumors with NRF2 activating mutations (Fig 3 and Table 2), assumed to be clonal. NRF2_SC: tumors with NRF2 activating mutations (Fig 3 and Table 2), assumed to be sub-clonal on the basis of low allele ratio. POLE: POLE exonuclease domain mutated tumors. TP53: TP53/copy-number high-like tumors.

S4 Fig. Endometrial carcinoma clustering based on NRF2 target gene expression in the TCGA cohort, based on principal component analysis. Clustering was based on principal component analysis. PC1 and PC2: principal component 1 and 2. POLE: POLE molecular tumor group; MSI: microsatellite instable tumor; NRF2: tumors bearing a missense mutation within the NRF2/KEAP1 binding domains on NFE2L2 (DLG and ETGE motifs) or missense mutation on KEAP1 (aa 324–597) coding sequences or KEAP1 truncating mutations. Principal component analysis used RNA-seq RSEM (V2) data available at the www.cbioportal.org portal.

S5 Fig. Endometrial carcinoma clustering based on NRF2 target gene expression in the TCGA cohort—heatmap. Unsupervised hierarchical clustering depicted using heatmap. Data: RNA-seq RSEM (V2) gene expression data available at the www.cbioportal.org portal. Genes considered belong to a NRF2 transcriptional signature including genes overlapping between two gene lists: genes repressed by a NFE2L2 siRNA-based silencing in A549 cells, a lung cancer cell line with a KEAP1 mutation (Mitsuishi et al. Cancer Cell 2012 Jul; 10:22 (1):66–79) & genes significantly overexpressed in lung carcinoma KEAP1- or NFE2L2-mutated (TCGA dataset, Nature 2014–230 cases) versus double wild-type carcinoma. Annotations depict mutations in signaling pathway of specific interest.

S6 Fig. NRF2 target gene expressions according to endometrial carcinoma molecular group in Cochin Hospital Cohort and in The Cancer Genome Atlas Cohort—full results. A-C: Cochin Hospital cohort (CCH). POLE: POLE exonuclease domain mutated tumors. MSI: microsatellite instable-like tumors. TP53: TP53/copy-number high-like tumors. CNL: copy number low-like tumors. Note that the 3 outliers in NQO1 and AKR1C3 plots are samples bearing clonal NRF2 pathway alterations (Fig 3). p-values are estimated using a post-hoc test adjusted for the risk α for multiple comparisons. Note that POLE tumors were not included in the post-hoc test because of the number of samples in the group (<5). D-F: The Cancer Genome Atlas Cohort (TCGA). POLE: POLE tumors. MSI: microsatellite instable tumors. NS: p > 0.05 *: p ≤ 0.05. **: p ≤ 0.01. ***: p ≤ 0.001. ****: p ≤ 0.0001. ANOVA: analysis of variance. p-values depicted in * to **** for graphical purposes and estimated using post-hoc test adjusted for the risk α for multiple comparisons.

S7 Fig. NQO1 expression according to estrogen receptor positivity and histological type in TP53/CNH-like tumors in Cochin Hospital cohort. Type I and type II carcinoma: see Table 1 for distribution and details. Estrogen receptor positivity: assessed using standard immunohistochemistry assay: tumors were considered positive if staining intensity was ≥+ in more than
10% tumors cells.

S8 Fig. NRF2 core target genes expressions according to KRAS and PI3K pathways mutations in Cochin Hospital cohort. CCH: Cochin Hospital cohort.

S9 Fig. NQO1 expression according to KRAS mutation in non-TP53/CNH-like tumors in Cochin Hospital cohort.

S1 Method. Targeted sequencing panel and coverage analysis.

S2 Method. NRF2 targeted sequencing panel and coverage analysis.

S3 Method. Variant Caller parameters.

S1 Dataset. Supporting information file. Clinical, histological and molecular characteristics of the 90 EC included in the study.

Author Contributions

Conceptualization: Guillaume Beinse, Pierre-Alexandre Just, Jérôme Alexandre, Karen Leroy.

Data curation: Guillaume Beinse, Bastien Rance.

Formal analysis: Guillaume Beinse, Bastien Rance.

Funding acquisition: Frederic Batteux, Bruno Borghese, Jérôme Alexandre.

Investigation: Guillaume Beinse, Pierre-Alexandre Just, Brigitte Izac, Franck Letourneur, Nathaniel Edward Bennett Saidu, Sandrine Chouzenoux, Carole Nicco, Eric Pasmant, Jérôme Alexandre, Karen Leroy.

Methodology: Eric Pasmant.

Project administration: Bruno Borghese, Jérôme Alexandre, Karen Leroy.

Resources: Pierre-Alexandre Just, Bastien Rance, François Goldwasser, Eric Pasmant, Frederic Batteux, Jérôme Alexandre.

Supervision: Frederic Batteux, Bruno Borghese, Jérôme Alexandre, Karen Leroy.

Validation: Guillaume Beinse, Pierre-Alexandre Just, Jérôme Alexandre, Karen Leroy.

Visualization: Guillaume Beinse, Pierre-Alexandre Just.

Writing – original draft: Guillaume Beinse.

Writing – review & editing: Pierre-Alexandre Just, François Goldwasser, Jérôme Alexandre, Karen Leroy.

References

1. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet. 2016; 387: 1084–1108. https://doi.org/10.1016/S0140-6736(15)00130-0
2. Getz G, Gabriel SB, Cibulskis K, Lander E, Sivachenko A, Sougnez C, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67–73. https://doi.org/10.1038/nature12113 PMID: 23636398

3. Taguchi K, Yamamoto M. The KEAP1-NRF2 System in Cancer. Front Oncol. 2017; 7: 85. https://doi.org/10.3389/fonc.2017.00085 PMID: 28523248

4. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013; 12: 931–947. https://doi.org/10.1038/nrd4002 PMID: 24287777

5. Chorley BN, Campbell MR, Wang X, Karaca M, Sambandan D, Bangura F, et al. Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res. 2012; 40: 7416–7429. https://doi.org/10.1093/nar/gks409 PMID: 22581777

6. Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happe C, et al. Global mapping of binding sites for Nrf2 identifies novel target cells in survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 2010; 38: 5718–5734. https://doi.org/10.1093/nar/gk212 PMID: 20460467

7. Kuosmanen SM, Viitala S, Laitinen T, Peräkylä M, Pölönen P, Kansanen E, et al. The Effects of Sequence Variation on Genome-wide NRF2 Binding—New Target Genes and Regulatory SNPs. Nucleic Acids Res. 2016; 44: 1760–1775. https://doi.org/10.1093/nar/gks409 PMID: 22581777

8. Türei D, Papp D, Fazekas D, Földvári-Nagy L, Módos D, Lent K, et al. NRF2-ome: an integrated web resource to discover protein interaction and regulatory networks of NRF2. Oxid Med Cell Longev. 2013; 2013: 737591. https://doi.org/10.1155/2013/737591 PMID: 23710289

9. Hast BE, Cloer EW, Goldfarb D, Li H, Siesser PF, Yan F, et al. Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination. Cancer Res. 2014; 74: 808–817. https://doi.org/10.1158/0008-5472.CAN-13-1655 PMID: 24322982

10. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, et al. Gain of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 2008; 68: 1303–1309. https://doi.org/10.1158/0008-5472.CAN-07-5003 PMID: 18316592

11. Jiang T, Chen N, Zhao F, Wang X-J, Kong B, Zheng W, et al. High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer. Cancer Res. 2010; 70: 5486–5496. https://doi.org/10.1158/0008-5472.CAN-10-0713 PMID: 20530669

12. Kemmerer ZA, Ader NR, Mulroy SS, Egglar AL. Comparison of human Nrf2 antibodies: A tale of two proteins. Toxicol Lett. 2015; 238: 83–89. https://doi.org/10.1016/j.toxlet.2015.07.004 PMID: 26220517

13. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013; 14: 178–192. https://doi.org/10.1093/bib/bbs017 PMID: 22517427

14. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011; 29: 24–26. https://doi.org/10.1038/nbt.1754 PMID: 21221095

15. Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 2018; 10: 25. https://doi.org/10.1186/s13073-018-0531-8 PMID: 29592813

16. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017:2017.
23. Hall G, Clark AJ, Langford E, Leung H, Eckstein RP, et al. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology (Phila). 2010; 42: 409–413. https://doi.org/10.3109/00313025.2010.493871 PMID: 20632815

24. Talhouk Aline, McConeney Melissa K., Leung Samuel, Yang Winnie, Lum Amy, Senz Janine, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123: 802–813. https://doi.org/10.1002/cncr.30496 PMID: 28061006

25. Kommoss S, McConeney MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol Off J Eur Soc Med Oncol. 2018; 29: 1180–1188. https://doi.org/10.1093/annonc/mdy058 PMID: 29432521

26. Jung K-A, Choi B-H, Nam C-W, Song M, Kim S-T, Lee JY, et al. Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Toxicol Lett. 2013; 218: 39–49. https://doi.org/10.1016/j.toxlet.2012.12.026 PMID: 23305850

27. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci. 2009; 34: 176–188. https://doi.org/10.1016/j.tibs.2008.12.008 PMID: 19321346

28. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6: pl1. https://doi.org/10.1126/scisignal.2004088 PMID: 23550210

29. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2: 401–404. https://doi.org/10.1158/2159-8290.CD-12-0095 PMID: 22588877

30. Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, et al. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res. 2014; 74: 7430–7441. https://doi.org/10.1158/0008-5472.CAN-14-1439 PMID: 25339352

31. Schermer M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17: 343–346. PMID: 889347

32. Li K, Zhong C, Wang B, He J, Bi J. Nrf2 expression participates in growth and differentiation of endometrial carcinoma cells in vitro and in vivo. J Mol Histol. 2014; 45: 161–167. https://doi.org/10.1007/s10735-013-9538-z PMID: 22899716

33. Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, et al. Mutant p53 R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of high levels of reactive oxygen species. J Cell Sci. 2012; 125: 5578–5586. https://doi.org/10.1242/jcs.106815 PMID: 22899716

34. Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol. 2016; 18: 897–909. https://doi.org/10.1038/ncllil.2016.94 PMID: 27347849

35. Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, et al. Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat Commun. 2017; 8: 14844. https://doi.org/10.1038/ncomms14844 PMID: 28348409

36. Vandenput I, Van Calster B, Capoen A, Leunen K, Berteloot P, Neven P, et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer. 2009; 101: 244–249. https://doi.org/10.1038/sj.bjc.660517 PMID: 19568245

37. Wardyn JD, Ponsford AH, Sanderson CM. Dissecting molecular cross-talk between Nrf2 and NF-κB response pathways. Biochem Soc Trans. 2015; 43: 621–626. https://doi.org/10.1042/BST20150014 PMID: 26551702